Most antibodies targeting SARS-CoV-2 use specific immunoglobulin subtype
Researchers reveal IgHV3-53 is the most common immunoglobulin mutation used to target the receptor binding domain on the SARS-CoV-2 spike protein.
List view / Grid view
Researchers reveal IgHV3-53 is the most common immunoglobulin mutation used to target the receptor binding domain on the SARS-CoV-2 spike protein.
Researchers reveal the Vav3 protein is responsible for the formation of bacterial docking stations in the airway cells which promote the recurrent lung infections seen in Cystic Fibrosis patients.
Scientists demonstrated that NELL2, a factor release by the testis, is essential for sperm to mature into motile cells able to fertilise an egg.
Scientists demonstrated that remdesivir can inhibit SARS-CoV-2 replication in human lung cells and improve lung function in mice with COVID-19.
The proteomic map based on data from 103 patients reveals novel prognostic biomarkers and potential drug targets for lung adenocarcinoma.
Researchers found breast cancer cells reprogrammed natural killer T cells, altering gene expression and receptor expression so they help cancerous metastases spread.
The bioreactor-based system incorporates liver cells to perform the detoxifying functions of the liver and was tested on pigs with acute liver failure.
Scientists identified a novel, highly specific drug target in the enzyme (sterol O-acyltransferase 1 (SOAT1)) cancer cells use to store cholesterol.
Researchers reveal a reduction in the number of eosinophil immune cells in belly fat with age may be the underlying cause of many age-related conditions with chronic low-grade inflammation.
The Brain Metastasis Cell Lines Panel compiles research from various international institutions on the numerous brain metastasis cell lines that have been developed, in hopes collaboration will expedite research and drug development.
The autonomous robot scientist can independently perform experimental procedures and makes its own decisions about which tests to perform.
Researchers report COVID-19 can cause a range of severe neurological symptoms, which may be the main presentation of COVID-19 in some patients.
Ophthalmology and engineering combine in a novel nanoparticle-delivered gene therapy approach to treating wet age-related macular degeneration.
The genomic research platform will initially be used to help fast-track COVID-19 drug research and development, before being leveraged against other diseases, such as cancer.
The vitamin K-based drug has a unique structure which researchers believe makes it effective in controlling even medication-resistant seizures.